Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 19;71(4):933–943. doi: 10.1093/cid/ciz889

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 4. — Absence of MF in the skin (intention to treat). A, The number of participants with/without MF at 18 months, after 2 annual/3 semiannual treatments (for all participants at 6 months after the last treatment). B, The number of participants with/without MF at 36 months, after 3 annual/5 semiannual treatments (for all participants at 12 months after the last treatment). C, The same participants as in panel A, at 18 months, but only grouped for annual or semiannual treatment, without taking the addition of ALB into account. D, The same participants as in panel B, at 36 months, but only grouped for annual or semiannual treatment, without taking the addition of ALB into account. Abbreviations: ALB, albendazole; IVM, ivermectin; MF, microfilaria.